News and Trends 3 Jun 2015
Erytech successfully completed its Phase III to ‘starve’ cancer cells to death
Erytech Pharma reported optimistic Phase III results of its pivotal program with GRASPA, an original treatment that targets cancer cells through “tumor starvation”. The positive results were presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO). Erytech Pharma’s technology makes it possible to “starve” cancer cells by depriving them of […]